Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Rare Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FREM2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FREM2 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View FREM2 Products |
| Gene Delivery | FREM2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for cell-based conformation preservation. |
View FREM2 Products |
| Benchmark Ab | Anti-FREM2 (Sequence of Research Leads) Recombinant positive control for assay validation. |
View FREM2 Products |
| Validator | FREM2 siRNA Set For knockdown verification and target specificity validation. |
View FREM2 Products |
| Related Target A | FRAS1 Forms a ternary adhesion complex with FREM2; critical for off-target and complex-specific screening. |
View FRAS1 Products |
| Related Target B | FREM1 Homologous extracellular matrix protein; essential for selectivity and counter-screening panels. |
View FREM1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity |
| Subfamily counter screening | Homolog panel proteins (FRAS1, FREM1) strictly verified by mass spectrometry and theoretical MW |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration |
| False Positives | Validated siRNA included for specificity and knock-down checks |
Live FREM2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FREM2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and cell therapies targeting solid tumors. As first-generation therapies reach the clinic, the next wave of R&D is targeting highly specific extracellular epitopes to avoid systemic toxicities associated with Fraser syndrome-related pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Biotech Innovators | Glioblastoma, Solid Tumors | Internalization Assay (Need high-purity ECD-Fc to track endocytosis kinetics) |
| CAR-T / Cell Therapy | Academic Medical Centers | Glioblastoma Multiforme (GBM) | Target Density & Specificity Validation (Need Lentivirus for Stable Cell Lines) |
| Monoclonal Antibody | Oncology Therapeutics Corp | Epithelial Cancers | Selectivity Assay (Need Mutant vs WT Proteins to map functional epitopes) |